Covid-19 transmission, testing, and vaccination dynamics within migrant worker social networks
Project Number1R21AI182822-01
Contact PI/Project LeaderSCHNEIDER, JOHN
Awardee OrganizationUNIVERSITY OF CHICAGO
Description
Abstract Text
This developmental research grant award (R21) requests funds to characterize the social and transmission
networks of migrant workers in Greece as part of pandemic preparedness, to mitigate ongoing and future
coronavirus epidemics among vulnerable populations in diverse contexts. We aim to better understand
COVID-19 prevention, testing, treatment, vaccination, seroprevalence and immunogenicity in order to address
facilitators and barriers to COVID-19 prevention. Migrant workers comprise one of the foremost essential
worker categories, are at increased risk of COVID-19 transmission and at the same time have some of the
lowest rates of testing and vaccination. Critical to public health is improving COVID-19 prevention among these
populations and their larger social networks. Network analysis can better illuminate ongoing transmission
dynamics and the potential for future epidemics. Contact tracing and other strategies do not fully include the
larger social network and data are often limited due to the stigma associated with providing named contacts, as
well as mistrust in government, particularly for migrant workers subject to harsh immigration policies. Social
network analysis, following traditional egocentric network approaches that this team has expertise in, can
illuminate multiple networks (family, workplace, acquaintance) and develop metrics tied to disease
transmission such as density, bridging and transitivity. In addition, network analysis can better explain
transmission potential phenomena such as sharing of resources across household units, workplace networks
and other transmission potentials. Understanding the potential transmission dynamics would help develop
tailored interventions to limit the explosive transmission documented in the US and Europe. The study context
and team are ideal for this proposal. Athens Greece is the entry point to the largest migrant population in the
EU and Bangladeshi migrants are the second largest constituency. Although the target population is very
specific, it represents an extremely important stream of global migration that connects two populous world
regions, with salient epidemiological consequences for the entire globe. The PI has a track record of
collaborative work implementing participant recruitment protocols in Athens among vulnerable populations
through street based and community focused engagement. The PI and site-PI are joined by additional experts
in virology, demography and South Asian and migrant health. Accordingly, we aim to: 1) Characterize the
social networks of Bangladeshi migrant workers in Athens and measure features of their network structures -
degree, density and bridging – most relevant to COVID-19 transmission potential; 2) Determine individual (ie.
age, gender), contextual (ie employment type), network and structural (stigma, health care access) factors
associated temporally with SARS-CoV-2 infection, seroprevalence and immunogenicity status. We will collect
survey data and biologic samples to model COVID-19 transmission; and 3) Determine individual and network
level factors associated with prevention behaviors: social distancing, masking, testing and vaccination.
Public Health Relevance Statement
This proposal requests funds to characterize the social and transmission networks of migrant workers in
Greece to mitigate ongoing and future coronavirus epidemics among vulnerable populations in diverse
contexts. We aim to better understand COVID-19 prevention, testing, treatment, vaccination, seroprevalence
and immunogenicity in order to address facilitators and barriers to COVID-19 transmission mitigation. Critical
to public health is improving COVID-19 prevention among these populations and their larger social networks.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
005421136
UEI
ZUE9HKT2CLC9
Project Start Date
05-March-2024
Project End Date
31-January-2026
Budget Start Date
05-March-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$275,261
Direct Costs
$219,715
Indirect Costs
$55,546
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$275,261
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI182822-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI182822-01
Patents
No Patents information available for 1R21AI182822-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI182822-01
Clinical Studies
No Clinical Studies information available for 1R21AI182822-01
News and More
Related News Releases
No news release information available for 1R21AI182822-01
History
No Historical information available for 1R21AI182822-01
Similar Projects
No Similar Projects information available for 1R21AI182822-01